MediCult's Media Promotes Adult Stem Cell Growth
Product News Jul 13, 2007
MediCult a/s has announced that it has demonstrated that its Synthetic Serum Replacement Media supports the growth of adult stem cells (mesenchymal stem cells).
The proof of concept study showed that it is possible to grow early mesenchymal stem cells for periods of up to at least 3 months in this completely characterized, protein-free, medium. Furthermore the cells remained capable of subsequent differentiation.
MediCult’s SSR medium is being developed to offer researchers in academia and pharma a means to grow stem cells for a broad set of applications, including research, toxicology, drug discovery and therapeutic development. As all constituents are known and controlled, the SSR medium could provide the optimal conditions to control growth and differentiation of stem cells by removing any potential effect induced by naturally occurring growth factors that may adhere to blood derived protein supplements.
As the data shows that the SSR medium provides a basis for both growth and subsequent stem cell differentiation, MediCult will now validate the findings in collaboration with external stem cell experts.
First results of the external validation are expected by end of 2007. Subsequently MediCult intends to broaden its efforts within this field to also address the need for growth media for human embryonic stem cells. Preliminary information on the viability of the concept in hESC (human embryonic stem cells) is expected in the beginning of 2008.
“The growing use and diverse applications of stem cells are having a significant impact on the media market. We believe that the possibility to make protein-free media is the key differentiator to other currently available stem cell media and that this will impact significantly the potential to develop this area, particularly as the regulatory environment continues to evolve,” noted Jesper Funding Andersen, CEO of MediCult.
“The commercial market for therapeutic, drug discovery or research usage of human stem cells is still in its infancy and no well-documented numbers estimate the commercial potential of this market. However it is believed that the market will be very substantial,” Andersen added.